Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.

Dreskin SC, Germinaro M, Reinhold D, Chen X, Vickery BP, Kulis M, Burks AW, Negi SS, Braun W, Chambliss JM, Eglite S, McNulty CMG.

Pediatr Allergy Immunol. 2019 Aug 22. doi: 10.1111/pai.13117. [Epub ahead of print]

PMID:
31437325
2.

Can Omalizumab Monotherapy Benefit Real-World Food Allergy Patients? Lessons From an Observational Study.

Vickery BP.

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1910-1911. doi: 10.1016/j.jaip.2019.05.007. No abstract available.

PMID:
31279468
3.

Oral Immunotherapy for Peanut Allergy.

Vickery BP, Hourihane JO, Adelman DC.

N Engl J Med. 2019 Feb 14;380(7):691-692. doi: 10.1056/NEJMc1817331. No abstract available.

PMID:
30763186
4.

Current and Future Treatment of Peanut Allergy.

Vickery BP, Ebisawa M, Shreffler WG, Wood RA.

J Allergy Clin Immunol Pract. 2019 Feb;7(2):357-365. doi: 10.1016/j.jaip.2018.11.049.

PMID:
30717866
5.

Prevention of food allergy: Beyond peanut.

Bird JA, Parrish C, Patel K, Shih JA, Vickery BP.

J Allergy Clin Immunol. 2019 Feb;143(2):545-547. doi: 10.1016/j.jaci.2018.12.993. Epub 2019 Jan 4. No abstract available.

PMID:
30611674
6.

AR101 Oral Immunotherapy for Peanut Allergy.

PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ibáñez MD, Tilles S, Assa’ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC Jr, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fernández-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, Burks AW.

N Engl J Med. 2018 Nov 22;379(21):1991-2001. doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18.

PMID:
30449234
7.

Evaluating primary end points in peanut immunotherapy clinical trials.

Rodríguez Del Río P, Escudero C, Sánchez-García S, Ibáñez MD, Vickery BP.

J Allergy Clin Immunol. 2019 Feb;143(2):494-506. doi: 10.1016/j.jaci.2018.09.035. Epub 2018 Oct 24.

PMID:
30367908
8.

High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.

Kulis M, Yue X, Guo R, Zhang H, Orgel K, Ye P, Li Q, Liu Y, Kim E, Burks AW, Vickery BP.

Clin Exp Allergy. 2019 Feb;49(2):180-189. doi: 10.1111/cea.13256. Epub 2018 Sep 18.

PMID:
30126028
9.

Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research.

Chehade M, Jones SM, Pesek RD, Burks AW, Vickery BP, Wood RA, Leung DYM, Furuta GT, Fleischer DM, Henning AK, Dawson P, Lindblad RW, Sicherer SH, Abonia JP, Sherrill JD, Sampson HA, Rothenberg ME.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1534-1544.e5. doi: 10.1016/j.jaip.2018.05.038. Epub 2018 Aug 1.

10.

Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.

Kottyan LC, Maddox A, Braxton JR, Stucke EM, Mukkada V, Putnam PE, Abonia JP, Chehade M, Wood RA, Pesek RD, Vickery BP, Furuta GT, Dawson P, Sampson HA, Martin LJ, Kelly JA, Kimberly RP, Sivils K, Gaffney PM, Kaufman K, Harley JB, Rothenberg ME.

Genes Immun. 2019 Apr;20(4):281-292. doi: 10.1038/s41435-018-0034-z. Epub 2018 Jun 8.

11.

Immune mechanisms of oral immunotherapy.

Kulis MD, Patil SU, Wambre E, Vickery BP.

J Allergy Clin Immunol. 2018 Feb;141(2):491-498. doi: 10.1016/j.jaci.2017.12.979. Epub 2017 Dec 26. Review.

PMID:
29288078
12.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.

Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis BP, Heimall J, Cianferoni A, MacGinnitie AJ, Crestani E, Burks AW; ARC001 Study Group.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):476-485.e3. doi: 10.1016/j.jaip.2017.09.016. Epub 2017 Oct 31.

13.

A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders.

Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, Gersuk VH, DeBerg HA, Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam9171. doi: 10.1126/scitranslmed.aam9171.

14.

Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products.

Filep S, Block DS, Smith BRE, King EM, Commins S, Kulis M, Vickery BP, Chapman MD.

J Allergy Clin Immunol. 2018 Feb;141(2):626-631.e7. doi: 10.1016/j.jaci.2017.05.049. Epub 2017 Jul 12.

PMID:
28709968
15.

Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.

Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, Henning AK, Berin MC, Chiang D, Vickery BP, Pesek RD, Cho CB, Davidson WF, Plaut M, Sampson HA, Wood RA; Consortium of Food Allergy Research.

J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9. doi: 10.1016/j.jaci.2016.08.017. Epub 2016 Oct 26.

PMID:
28091362
16.

Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab.

Burk CM, Dellon ES, Steele PH, Virkud YV, Kulis M, Burks AW, Vickery BP.

J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):498-501. doi: 10.1016/j.jaip.2016.11.010. Epub 2016 Dec 22. No abstract available.

17.

Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy.

Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, Scurlock AM, Perry TT, Pesek RD, Vickery BP.

J Allergy Clin Immunol. 2017 Mar;139(3):882-888.e5. doi: 10.1016/j.jaci.2016.07.030. Epub 2016 Sep 5.

18.

Low dose immunotherapy in very young children to treat peanut allergy.

Vickery BP.

Expert Rev Clin Immunol. 2016 Dec;12(12):1251-1253. Epub 2016 Sep 12. No abstract available.

19.

Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2.

Orgel KA, Duan S, Wright BL, Maleki SJ, Wolf JC, Vickery BP, Burks AW, Paulson JC, Kulis MD, Macauley MS.

J Allergy Clin Immunol. 2017 Jan;139(1):366-369.e2. doi: 10.1016/j.jaci.2016.06.053. Epub 2016 Aug 20. No abstract available.

20.

Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.

Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, Keet CA, Kulis M, Orgel KG, Guo R, Steele PH, Virkud YV, Ye P, Wright BL, Wood RA, Burks AW.

J Allergy Clin Immunol. 2017 Jan;139(1):173-181.e8. doi: 10.1016/j.jaci.2016.05.027. Epub 2016 Aug 10.

21.

Food-specific IgG4 is associated with eosinophilic esophagitis.

Wright BL, Kulis M, Guo R, Orgel KA, Wolf WA, Burks AW, Vickery BP, Dellon ES.

J Allergy Clin Immunol. 2016 Oct;138(4):1190-1192.e3. doi: 10.1016/j.jaci.2016.02.024. Epub 2016 Apr 6. No abstract available.

22.

Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Wright BL, Kulis M, Orgel KA, Burks AW, Dawson P, Henning AK, Jones SM, Wood RA, Sicherer SH, Lindblad RW, Stablein D, Leung DY, Vickery BP, Sampson HA; Consortium of Food Allergy Research.

Allergy. 2016 Nov;71(11):1552-1560. doi: 10.1111/all.12895. Epub 2016 Jun 13.

23.

Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.

Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, Liu AH, Sicherer SH, Henning AK, Lindblad RW, Dawson P, Berin C, Fleischer DM, Leung DYM, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR).

J Allergy Clin Immunol. 2016 Apr;137(4):1117-1127.e10. doi: 10.1016/j.jaci.2015.12.1316. Epub 2016 Mar 9.

24.

Impact of Allergic Reactions on Food-Specific IgE Concentrations and Skin Test Results.

Sicherer SH, Wood RA, Vickery BP, Perry TT, Jones SM, Leung DY, Blackwell B, Dawson P, Burks AW, Lindblad R, Sampson HA.

J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):239-45.e4. doi: 10.1016/j.jaip.2015.11.015. Epub 2015 Dec 21.

25.

Oral Immunotherapy for Food Allergy.

Burbank AJ, Sood P, Vickery BP, Wood RA.

Immunol Allergy Clin North Am. 2016 Feb;36(1):55-69. doi: 10.1016/j.iac.2015.08.007. Review.

PMID:
26617227
26.

Current Options for the Treatment of Food Allergy.

Lanser BJ, Wright BL, Orgel KA, Vickery BP, Fleischer DM.

Pediatr Clin North Am. 2015 Dec;62(6):1531-49. doi: 10.1016/j.pcl.2015.07.015. Epub 2015 Sep 7. Review.

27.

Clinical Management of Food Allergy.

Wright BL, Walkner M, Vickery BP, Gupta RS.

Pediatr Clin North Am. 2015 Dec;62(6):1409-24. doi: 10.1016/j.pcl.2015.07.012. Epub 2015 Sep 7. Review.

28.

Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.

Burk CM, Kulis M, Leung N, Kim EH, Burks AW, Vickery BP.

Clin Exp Allergy. 2016 Feb;46(2):347-53. doi: 10.1111/cea.12635.

29.

Does clinical protection persist after food allergen oral immunotherapy?

Vickery BP.

Immunotherapy. 2015;7(8):851-3. doi: 10.2217/imt.15.59. Epub 2015 Aug 28. No abstract available.

PMID:
26314347
30.

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.

Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, Vickery BP, Liu AH, Henning AK, Lindblad R, Dawson P, Plaut M, Sampson HA; Consortium of Food Allergy Research.

J Allergy Clin Immunol. 2015 May;135(5):1240-8.e1-3. doi: 10.1016/j.jaci.2014.12.1917. Epub 2015 Feb 3.

31.

Food allergies affect growth in children.

Hobbs CB, Skinner AC, Burks AW, Vickery BP.

J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):133-4.e1. doi: 10.1016/j.jaip.2014.11.004. Epub 2014 Nov 25. No abstract available.

32.

Allergist-reported trends in the practice of food allergen oral immunotherapy.

Greenhawt MJ, Vickery BP.

J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):33-8. doi: 10.1016/j.jaip.2014.06.023. Epub 2014 Oct 29.

33.

The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch.

Moran TP, Vickery BP.

Pediatrics. 2014 Nov;134 Suppl 3:S160-1. doi: 10.1542/peds.2014-1817VV. No abstract available.

34.

Food allergy: a practice parameter update-2014.

Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, Nadeau K, Nowak-Wegrzyn A, Oppenheimer J, Perry TT, Randolph C, Sicherer SH, Simon RA, Vickery BP, Wood R; Joint Task Force on Practice Parameters, Bernstein D, Blessing-Moore J, Khan D, Lang D, Nicklas R, Oppenheimer J, Portnoy J, Randolph C, Schuller D, Spector S, Tilles SA, Wallace D; Practice Parameter Workgroup, Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, Nadeau K, Nowak-Wegrzyn A, Oppenheimer J, Perry TT, Randolph C, Sicherer SH, Simon RA, Vickery BP, Wood R.

J Allergy Clin Immunol. 2014 Nov;134(5):1016-25.e43. doi: 10.1016/j.jaci.2014.05.013. Epub 2014 Aug 28.

PMID:
25174862
35.

Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.

Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, Weirauch MT, Vaughn S, Lazaro S, Rupert AM, Kohram M, Stucke EM, Kemme KA, Magnusen A, He H, Dexheimer P, Chehade M, Wood RA, Pesek RD, Vickery BP, Fleischer DM, Lindbad R, Sampson HA, Mukkada VA, Putnam PE, Abonia JP, Martin LJ, Harley JB, Rothenberg ME.

Nat Genet. 2014 Aug;46(8):895-900. doi: 10.1038/ng.3033. Epub 2014 Jul 13.

36.

The natural history of egg allergy in an observational cohort.

Sicherer SH, Wood RA, Vickery BP, Jones SM, Liu AH, Fleischer DM, Dawson P, Mayer L, Burks AW, Grishin A, Stablein D, Sampson HA.

J Allergy Clin Immunol. 2014 Feb;133(2):492-9. doi: 10.1016/j.jaci.2013.12.1041.

37.

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.

Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW.

J Allergy Clin Immunol. 2014 Feb;133(2):468-75. doi: 10.1016/j.jaci.2013.11.007. Epub 2013 Dec 19.

38.

Oral and sublingual immunotherapy for food allergy: current progress and future directions.

Moran TP, Vickery BP, Burks AW.

Curr Opin Immunol. 2013 Dec;25(6):781-7. doi: 10.1016/j.coi.2013.07.011. Epub 2013 Aug 20. Review.

39.

Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison.

Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, Scurlock AM, Jones SM, Burks AW.

J Allergy Clin Immunol. 2013 Aug;132(2):476-8.e2. doi: 10.1016/j.jaci.2013.02.017. Epub 2013 Mar 25. No abstract available.

40.

The natural history of milk allergy in an observational cohort.

Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, Henning AK, Mayer L, Burks AW, Grishin A, Stablein D, Sampson HA.

J Allergy Clin Immunol. 2013 Mar;131(3):805-12. doi: 10.1016/j.jaci.2012.10.060. Epub 2012 Dec 28.

41.

Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.

Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablein D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR).

J Allergy Clin Immunol. 2013 Jan;131(1):119-27.e1-7. doi: 10.1016/j.jaci.2012.11.011.

42.

Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.

Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, Scurlock AM, Gimenez G, Bardina L, Sampson HA, Burks AW.

J Allergy Clin Immunol. 2013 Jan;131(1):128-34.e1-3. doi: 10.1016/j.jaci.2012.10.048. Epub 2012 Nov 27.

43.

Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT).

Bird JA, Kulis M, Burk CM, Vickery BP, Jones SM, Burks W.

Ann Allergy Asthma Immunol. 2012 Dec;109(6):470-1. doi: 10.1016/j.anai.2012.09.004. Epub 2012 Oct 4. No abstract available.

PMID:
23176890
44.

Advances in immunotherapy for food allergy.

Virkud YV, Vickery BP.

Discov Med. 2012 Sep;14(76):159-65. Review.

45.

Pathogenesis of food allergy in the pediatric patient.

Chin S, Vickery BP.

Curr Allergy Asthma Rep. 2012 Dec;12(6):621-9. doi: 10.1007/s11882-012-0296-x. Review.

46.

Oral immunotherapy for treatment of egg allergy in children.

Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR).

N Engl J Med. 2012 Jul 19;367(3):233-43. doi: 10.1056/NEJMoa1200435.

47.

Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.

Thyagarajan A, Jones SM, Calatroni A, Pons L, Kulis M, Woo CS, Kamalakannan M, Vickery BP, Scurlock AM, Wesley Burks A, Shreffler WG.

Clin Exp Allergy. 2012 Aug;42(8):1197-205. doi: 10.1111/j.1365-2222.2012.04028.x.

48.

Egg oral immunotherapy.

Vickery BP.

Curr Opin Allergy Clin Immunol. 2012 Jun;12(3):278-82. doi: 10.1097/ACI.0b013e3283535bae. Review.

PMID:
22488105
49.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.

Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, Staats H, Burks AW.

J Allergy Clin Immunol. 2012 Apr;129(4):1159-62. doi: 10.1016/j.jaci.2011.11.045. Epub 2012 Jan 10. No abstract available.

50.

Anaphylaxis from peanuts ingested by blood donors?

Vickery BP, Burks AW, Sampson HA.

N Engl J Med. 2011 Sep 1;365(9):867-8; author reply 868. doi: 10.1056/NEJMc1106934. No abstract available.

PMID:
21879920

Supplemental Content

Loading ...
Support Center